FY2025 Earnings Estimate for TSE:MDP Issued By Stifel Canada

Medexus Pharmaceuticals Inc. (TSE:MDP) – Equities researchers at Stifel Canada increased their FY2025 earnings estimates for shares of Medexus Pharmaceuticals in a research note issued on Monday, January 13th. Stifel Canada analyst J. Keywood now anticipates that the company will earn $0.03 per share for the year, up from their prior forecast of ($0.03). The consensus estimate for Medexus Pharmaceuticals’ current full-year earnings is $0.16 per share.

Several other brokerages have also recently weighed in on MDP. Leede Financial set a C$8.25 target price on Medexus Pharmaceuticals and gave the stock a “speculative buy” rating in a report on Monday, September 30th. Alliance Global Partners upgraded Medexus Pharmaceuticals to a “strong-buy” rating in a report on Monday, December 23rd. Raymond James upgraded shares of Medexus Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a C$4.00 target price on the stock in a report on Wednesday, January 8th. Finally, Stifel Nicolaus boosted their price target on shares of Medexus Pharmaceuticals from C$4.15 to C$4.50 in a report on Tuesday. Two equities research analysts have rated the stock with a buy rating and four have issued a strong buy rating to the company’s stock. According to MarketBeat.com, Medexus Pharmaceuticals presently has an average rating of “Strong Buy” and a consensus target price of C$5.58.

Medexus Pharmaceuticals Stock Performance

Shares of TSE MDP opened at C$4.30 on Thursday. The stock has a 50 day moving average price of C$3.00 and a 200 day moving average price of C$2.63. The firm has a market capitalization of C$105.48 million, a price-to-earnings ratio of 86.00 and a beta of 1.96. Medexus Pharmaceuticals has a 52-week low of C$1.47 and a 52-week high of C$4.60.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.